Content deleted Content added
Nereocystis (talk | contribs) Add Cochrane review of studies for TMS treating depression. |
m fixed 3x invalid ref position using ARA |
||
Line 102:
===Depression===
The National Institutes of Health estimates depression medications work for 60 percent to 70 percent of people who take them.<ref>{{cite book | url=https://www.ncbi.nlm.nih.gov/books/NBK20369/|title= Information about Mental Illness and the Brain|year= 2007|publisher= National Institutes of Health (US)}}</ref><ref> In addition, the World Health Organization reports that the number of people living with depression has increased nearly 20 percent since 2005.</ref> It is approved as a Class II medical device under the "''de novo'' pathway".<ref>Michael Drues, for Med Device Online. 5 February 2014 [http://www.meddeviceonline.com/doc/secrets-of-the-de-novo-pathway-part-why-aren-t-more-device-makers-using-it-0001 Secrets Of The De Novo Pathway, Part 1: Why Aren't More Device Makers Using It?]</ref><ref name=2015revPain>{{cite journal | vauthors = Schwedt TJ, Vargas B | title = Neurostimulation for Treatment of Migraine and Cluster Headache | journal = Pain Medicine | volume = 16 | issue = 9 | pages = 1827–1834 | date = September 2015 | pmid = 26177612 | pmc = 4572909 | doi = 10.1111/pme.12792 }}</ref> In addition, the World Health Organization reports that the number of people living with depression has increased nearly 20 percent since 2005.<ref>{{Cite web |title="Depression: let's talk" says WHO, as depression tops list of causes of ill health |url=https://www.who.int/news/item/30-03-2017--depression-let-s-talk-says-who-as-depression-tops-list-of-causes-of-ill-health |access-date=2022-08-10 |website=www.who.int |language=en}}</ref> In a 2012 study, TMS was found to improve depression significantly in 58 percent of patients and provide complete remission of symptoms in 37 percent of patients.<ref>{{cite journal |vauthors=Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook IA, Dunner DL, Lanocha K, Solvason HB, Demitrack MA |title=Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice |journal=Depress Anxiety |volume=29 |issue=7 |pages=587–96 |date=July 2012 |pmid=22689344 |doi=10.1002/da.21969 |s2cid=22968810 |url=}}</ref> In 2002, Cochrane Library reviewed randomized controlled trials using TMS to treat depression. The review did not find a difference between rTMS and sham TMS, except for a period 2 weeks after treatment.
=== Obsessive–compulsive disorder (OCD) ===
Line 109:
In 2020, US FDA authorized the use of TMS developed by the U.S. company MagVenture Inc. in the treatment of OCD.<ref>{{Cite web |title=MagVenture receives FDA clearance for OCD {{!}} Clinical TMS Society |url=https://www.clinicaltmssociety.org/news/2020-08/magventure-receives-fda-clearance-ocd-0 |access-date=2023-10-11 |website=www.clinicaltmssociety.org}}</ref>
In 2023, US FDA authorized the use of TMS developed by the U.S. company Neuronetics Inc. in the treatment of OCD.
====Other neurological areas====
| |||